Detalhe da pesquisa
1.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
J Int AIDS Soc;
25(6): e25905, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36039892
2.
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Lancet HIV;
6(9): e588-e600, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31371262
3.
High prevalence of sexually transmitted infections among women screened for a contraceptive intravaginal ring study, Kisumu, Kenya, 2014.
Int J STD AIDS;
29(14): 1390-1399, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30071799
4.
Factors associated with psychological distress among young women in Kisumu, Kenya.
Int J Womens Health;
9: 255-264, 2017.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28496366
5.
Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.
Contraception;
95(6): 602-604, 2017 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28372978
6.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
Artigo
em Inglês
| Arca: Repositório institucional da Fiocruz
| ID: arc-55522
7.
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
Artigo
em Inglês
| Arca: Repositório institucional da Fiocruz
| ID: arc-36767